Patients with Acute Coronary Syndrome (ACS) or suffering from both Atrial Fibrillation (AF) and Coronary Artery Disease (CAD) need an antiplatelet drug to prevent heart attacks. They also need an anticoagulant to prevent the formation of stroke-inducing blood clots. Historically, taking both long term has not been an option because of the dangerously heightened risk of uncontrolled bleeding.
Verseon is advancing the solution: Precision Oral Anticoagulants (PROACs) to prevent stroke from clots without inhibiting the body’s ability to prevent uncontrolled bleeds. These drugs will allow lifelong antiplatelet-anticoagulant combination therapy for Cardiovascular Disease (CVD) patients who currently have no option.
Cardio vascular disease patients in developed countries need long- term antiplatelet-anticoagulant combination therapy
Global combination therapy market